China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion
LLY•InnoCare and Eli Lilly sign research collaboration and license agreement
China's InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
Sept. 24 (Reuters) - Chinese drugmaker InnoCare Pharma said on Thursday it entered into a research collaboration and license agreement with Eli Lilly that could be worth up to about $3.35 billion.
